CareDx: Solid Near-Term Execution vs. Reimbursement Headwinds and Long-Dated Pipeline Upside Justify Hold Rating

H.C. Wainwright analyst Yi Chen has reiterated their neutral stance on CDNA stock, giving a Hold rating on February 26.

Yi Chen has given his Hold rating due to a combination of factors involving both solid recent performance and lingering uncertainties. CareDx delivered stronger‑than‑expected fourth‑quarter revenue and double‑digit full‑year growth, with notable gains in testing, product, and digital solutions, as well as improved cash conversion and reimbursement metrics that point to better operational execution.

At the same time, management’s 2026 outlook, while calling for mid‑teens revenue growth and positive adjusted EBITDA, is tempered by potential reimbursement headwinds, including a possible negative impact from a finalized LCD for solid organ transplant testing. Moreover, the promising AlloHeme cell therapy surveillance program, though strategically important, will not meaningfully contribute until its planned commercial rollout around 2027–2028, leaving a gap between near‑term fundamentals and longer‑term pipeline upside that supports maintaining a Neutral stance rather than upgrading the stock.

In another report released on February 26, TipRanks – OpenAI also downgraded the stock to a Hold with a $19.00 price target.